RNAZ - TransCode Therapeutics Market Capitalization-to-Revenue Ratio
TransCode Therapeutics focuses on developing RNA-based drugs to combat metastases, which provides short-term activity. In the long term, the scientific team's strategic course ensures transparency of R&D expenses. The company's P/S ratio visualizes this balance, where the level indicates the state of the revenue valuation parameter. Ultimate success depends on the outcome of tests amid a high cash burn rate.
Metric breakdowns and analytics for TransCode Therapeutics (RNAZ)
- current quotes and average value forecast:
- market capitalization statistics:
- book capitalization indicators:
- business debt structure and liquidity details:
Debt to Capital TransCode Therapeutics|RNAZ - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital transcodetherapeutics.com|RNAZ - Company Aggregate Debts|Debts to Book Capitalization TransCode|RNAZ - Company Long-Term Debt|Current Liabilities TransCode Therapeutics|Immediate Liquidity transcodetherapeutics.com
- earnings and market ratios statistics:
RNAZ - Net Income|Projected Future Earnings TransCode Therapeutics|RNAZ - Price to Earnings Ratio|Market Cap to Future Earnings Ratio transcodetherapeutics.com|RNAZ - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio TransCode|RNAZ - Operating profit EBITDA|Net earnings per share for the last 12 months TransCode Therapeutics|RNAZ - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months transcodetherapeutics.com|RNAZ - Earnings per share growth in current year|Expected earnings per share trend next year TransCode Therapeutics
- issuer revenue and sales details:
General company analysis:RNAZ TransCode Therapeutics Inc.
The P/S ratio measures the market value of TransCode Therapeutics (RNAZ) relative to its revenue, determining the premium investors are willing to pay per unit of sales. The fundamental P/S trend reflects the valuation's sensitivity to the commercialization of developments, where resilience to macro cycles is offset by the share price's dependence on the success of clinical trials and the adoption rates of innovative medical products.
Competitors of TransCode Therapeutics
TEM - Price to Sales|Qiagen - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN: Market Cap to Revenue|Avidity Corp - Market Cap to Sales Volume|CRSP: P/S Multiple|genedx.com - Market Capitalization-to-Revenue Ratio|RARE (Ultragenyx) - P/S Multiple|Price to Sales Beam Therapeutics Inc BEAM|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|TWST (Twist Bioscience Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple TXG (10x Genomics, Inc.)|P/S Multiple intelliatx.com NTLA|STOK - Price-to-Revenue Ratio|Price-to-Sales Ratio BLFS|WVE: P/S Multiple|Price to Sales Maze Therapeutics Corp (MAZE)|Market Cap to Revenue SION|P/S Multiple primemedicine.com|Market Cap to Revenue TSHA (Taysha Gene Therapies, Inc.)|Market Cap to Sales Volume QURE|P/S Multiple MGTX (MeiraGTx PLC)|Price-to-Revenue Coefficient REGENXBIO Corp (RGNX)|Solid Biosciences Inc. - P/S Multiple|ocugen.com (OCGN) - Market Cap to Revenue|PacBio (PACB) - Price-to-Revenue Ratio|BNTC - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Design Pharma|RCKT: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio 4D Molecular Therapeutics (FDMT)|lexeotx.com - Market Cap to Revenue Ratio|P/S Multiple KRRO (Korro Bio)|P/S Multiple Editas Medicine Inc EDIT|SLN: Market Cap to Revenue|Price-to-Sales Ratio PRQR|CDXS: P/S Multiple|Market Cap to Revenue Ratio SGMO|Price-to-Revenue Ratio Nautilus Biotechnology, Inc.|Market Cap to Revenue Ratio MGX (Metagenomi Inc.)|P/S Multiple DTIL|P/S Multiple generationbio.com (GBIO)|Boundless Bio, Inc. - Market Cap to Revenue|Market Cap to Sales Volume XCUR (Exicure Inc.)|IMNN - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio PHIO (Phio Pharmaceuticals)|MBIO: P/S Multiple|Bionano Genomics (BNGO) - P/S Multiple|Price-to-Revenue Ratio Applied DNA Sciences|Market Cap to Revenue Ratio BLUE (bluebirdbio.com)|Price-to-Revenue Ratio ImmunoPrecise Antibodies (IPA)|Price-to-Revenue Coefficient Omega Therapeutics Inc|P/S Multiple OMIC (Singular Genomics Systems Inc)|RGLS - Market Cap to Revenue|SYRS - Price-to-Revenue Ratio|Price to Sales telesisbio.com|TCON: P/S Multiple|Market Cap to Revenue Ratio UBX
